Cart
sales@molnova.com
VX-745
CAS No. 209410-46-8
VX-745( VX 745 | VX745 | Neflamapimod )
Catalog No. M13290 CAS No. 209410-46-8
A potent and selective p38α kinase inhibitor with IC50 of 9 nM; shows 20-fold selectivity for p38α over p38β (Ki=220 nM) and no significant inhibition for MAP kinases (with the exception of MKK6).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 45 | In Stock |
|
| 5MG | 41 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 25MG | 122 | In Stock |
|
| 50MG | 202 | In Stock |
|
| 100MG | 300 | In Stock |
|
| 200MG | 448 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVX-745
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective p38α kinase inhibitor with IC50 of 9 nM; shows 20-fold selectivity for p38α over p38β (Ki=220 nM) and no significant inhibition for MAP kinases (with the exception of MKK6).
-
DescriptionA potent and selective p38α kinase inhibitor with IC50 of 9 nM; shows 20-fold selectivity for p38α over p38β (Ki=220 nM) and no significant inhibition for MAP kinases (with the exception of MKK6); exhibits inhibition of PBMC IL-1β and TNFα IC50 of 45 and 51 nM, respectively; possesses favorable PK profile, and demonstrates good in vivo activity in models of inflammation.Alzheimer's Disease Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsVX 745 | VX745 | Neflamapimod
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38α|p38β
-
Research AreaNeurological Disease
-
IndicationAlzheimer Disease
Chemical Information
-
CAS Number209410-46-8
-
Formula Weight436.2621
-
Molecular FormulaC19H9Cl2F2N3OS
-
Purity>98% (HPLC)
-
SolubilityDMSO: 13.08 mg/mL (Need ultrasonic)
-
SMILESO=C1C(C2=C(Cl)C=CC=C2Cl)=C3C=CC(SC4=CC=C(F)C=C4F)=NN3C=N1
-
Chemical Name6H-Pyrimido[1,6-b]pyridazin-6-one, 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Duffy JP, et al. ACS Med Chem Lett. 2011 Jul 28;2(10):758-63.
2. McGuire VA, et al. Mol Cell Biol. 2013 Nov;33(21):4152-65.
3. Alam JJ. J Alzheimers Dis. 2015;48(1):219-27.
molnova catalog
related products
-
BMS-751324
BMS-751324 is a novel clinical prodrug of BMS-582949, which is a highly selective p38α MAPK inhibitor with IC50 of 13 nM.
-
Acumapimod
An orally active, potent p38 MAPK inhibitor that potently inhibits ex vivo LPS‐induced TNFα secretion with an IC50 of 44 ng/mL (115 nM).
-
BI-2865
BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively.
